[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201071137A1 - Способы лечения - Google Patents

Способы лечения

Info

Publication number
EA201071137A1
EA201071137A1 EA201071137A EA201071137A EA201071137A1 EA 201071137 A1 EA201071137 A1 EA 201071137A1 EA 201071137 A EA201071137 A EA 201071137A EA 201071137 A EA201071137 A EA 201071137A EA 201071137 A1 EA201071137 A1 EA 201071137A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
antibody
relates generally
fabs
Prior art date
Application number
EA201071137A
Other languages
English (en)
Inventor
Фредрик Э. Харгрив
Джампьетро Вентреска
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41114741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201071137A1 publication Critical patent/EA201071137A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится в целом к способам лечения и диагностики состояний, опосредованных IL-5 и избыточной продукцией эозинофилов, и, в частности, к mAbs, Fabs, химерным и гуманизированным антителам. Более конкретно, данное изобретение относится в целом к лечению эозинофильного бронхита с помощью антитела против IL-5 или фрагмента указанного антитела.
EA201071137A 2008-03-28 2009-03-27 Способы лечения EA201071137A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4036308P 2008-03-28 2008-03-28
PCT/US2009/038509 WO2009120927A2 (en) 2008-03-28 2009-03-27 Methods of treatment

Publications (1)

Publication Number Publication Date
EA201071137A1 true EA201071137A1 (ru) 2011-04-29

Family

ID=41114741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071137A EA201071137A1 (ru) 2008-03-28 2009-03-27 Способы лечения

Country Status (14)

Country Link
US (3) US9834600B2 (ru)
EP (1) EP2274009B1 (ru)
JP (4) JP5917143B2 (ru)
KR (1) KR20100134702A (ru)
CN (1) CN102026660A (ru)
AU (1) AU2009228163B2 (ru)
BR (1) BRPI0910854A2 (ru)
CA (1) CA2719786A1 (ru)
EA (1) EA201071137A1 (ru)
ES (1) ES2441945T3 (ru)
IL (1) IL208354A0 (ru)
MX (1) MX2010010667A (ru)
WO (1) WO2009120927A2 (ru)
ZA (1) ZA201006648B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CN102026660A (zh) 2008-03-28 2011-04-20 葛兰素史密斯克莱有限责任公司 治疗方法
CN102186350A (zh) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (pt) 2010-10-01 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos manipulados e métodos de uso dos mesmos.
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102014061B1 (ko) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
SI3191513T1 (sl) * 2014-09-08 2020-12-31 Cephalon, Inc. Uporaba reslizumaba za zdravljenje zmerne do hude eozinofilne astme
EP4056590A1 (en) 2015-08-24 2022-09-14 GlaxoSmithKline Intellectual Property (No.2) Limited Biopharmaceutical compositions
TWI799417B (zh) 2017-05-26 2023-04-21 英商葛蘭素史克智慧財產發展有限公司 生物製藥組成物及相關方法
IL300357A (en) * 2020-08-05 2023-04-01 Areteia Therapeutics Inc Use of DEXPRAMIPEXOLE to treat moderate to severe asthma

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
ES2062032T3 (es) 1988-11-03 1994-12-16 Schering Corp Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
KR100254759B1 (ko) 1992-01-23 2000-05-01 플레믹 크리스티안 단량체 및 이량체 항체-단편 융합 단백질
AU683836B2 (en) 1992-02-06 1997-11-27 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
WO1995014040A1 (en) 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
HU222992B1 (hu) 1994-12-23 2004-01-28 Smithkline Beecham Corporation IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6248723B1 (en) * 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
PL340606A1 (en) * 1997-10-22 2001-02-12 Jens Ponikau Methods of and materials for treating and preventing mucositis
WO2001012646A1 (en) 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies
US20030017169A1 (en) * 2000-12-29 2003-01-23 Sidney Pestka Controlled release systems for polymers
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US7339507B1 (en) * 2006-09-13 2008-03-04 Jiun-In Guo Device for video decoding
CN101558081B (zh) * 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
DK2152290T3 (da) 2007-04-30 2014-08-18 Glaxosmithkline Llc Fremgangsmåder til indgivelse af anti-il-5-antistoffer
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
CN102026660A (zh) * 2008-03-28 2011-04-20 葛兰素史密斯克莱有限责任公司 治疗方法
US8926631B2 (en) 2010-08-06 2015-01-06 MoMelan Technologies, Inc. Methods for preparing a skin graft without culturing or use of biologics
US10286037B2 (en) 2011-02-09 2019-05-14 Glaxosmithkline Llc Methods of producing lyophilized polypeptide composition formulations comprising volatile additives

Also Published As

Publication number Publication date
JP6457463B2 (ja) 2019-01-23
US20200071395A1 (en) 2020-03-05
ZA201006648B (en) 2011-07-27
US20110020339A1 (en) 2011-01-27
JP6069267B2 (ja) 2017-02-01
AU2009228163B2 (en) 2012-08-30
IL208354A0 (en) 2010-12-30
CN102026660A (zh) 2011-04-20
US20180057582A1 (en) 2018-03-01
JP2014240408A (ja) 2014-12-25
JP5917143B2 (ja) 2016-05-11
EP2274009B1 (en) 2013-11-13
EP2274009A2 (en) 2011-01-19
ES2441945T3 (es) 2014-02-07
US9834600B2 (en) 2017-12-05
JP2019065029A (ja) 2019-04-25
AU2009228163A1 (en) 2009-10-01
CA2719786A1 (en) 2009-10-01
EP2274009A4 (en) 2012-01-25
BRPI0910854A2 (pt) 2015-10-06
JP2011516422A (ja) 2011-05-26
KR20100134702A (ko) 2010-12-23
MX2010010667A (es) 2010-11-09
WO2009120927A2 (en) 2009-10-01
JP2017048224A (ja) 2017-03-09
US11325972B2 (en) 2022-05-10
WO2009120927A3 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
EA201071137A1 (ru) Способы лечения
NZ621170A (en) Anti-human cd52 immunoglobulins
JO3097B1 (ar) الأجسام المضادة c-Met
NZ611076A (en) Anti-ngf compositions and use thereof
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
TN2014000107A1 (en) Anti-aplhabetatcr antibody
WO2010039900A3 (en) Non-human mammals for the production of chimeric antibodies
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
EA201301295A1 (ru) Композиции антител против cgrp и их применение
EA200802168A1 (ru) Гуманизированное антитело к с-kit
AR079944A1 (es) Anticuerpo neutralizante de la actividad de un anticoagulante
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
NZ595235A (en) Compositions and methods for increasing muscle growth
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
NZ610734A (en) Human antibodies to the glucagon receptor
NZ611269A (en) Neutralizing anti-ccl20 antibodies
NZ602320A (en) Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
WO2012109280A3 (en) Apoe immunotherapy
EA201270124A1 (ru) Новые терапевтические и диагностические средства
WO2013177035A3 (en) Humaneered anti-factor b antibody